S. Harrison

发表

Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

J. Hardies, K. Cusi, A. Gastaldelli, 2012, Hepatology.

GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH

J. Dufour, S. Beckebaum, J. Trotter, 2019, Journal of Hepatology.

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum

B. Neuschwander‐Tetri, V. Miller, D. Kleiner, 2019, Hepatology.

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH

K. Cusi, V. Positano, A. Gastaldelli, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Current therapies and new developments in NASH

H. Tilg, V. Wong, V. Paradis, 2022, Gut.

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

K. Cusi, A. Feldstein, M. Goros, 2014, Journal of hepatology.

Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data

Suying Li, R. Loomba, R. Wong, 2020, Alimentary pharmacology & therapeutics.

BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study

B. Neuschwander‐Tetri, A. Sanyal, R. Loomba, 2017 .

Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial

K. Reddy, S. Belle, A. Wahed, 2019, PloS one.

Veillonella as a bile acid-sensitive bacteria and a microbiome-based biomarker for aldafermin (NGM282) in patients with non-alcoholic steatohepatitis

A. Sanyal, R. Loomba, Duy M. Dinh, 2020, Journal of Hepatology.

Simple diagnostic algorithm identifying at-risk nonalcoholic fatty liver disease patients needing specialty referral within the United States

M. Noureddin, N. Alkhouri, S. Harrison, 2022, World journal of hepatology.

Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial

S. Belle, A. Wahed, M. D'Amato, 2019, PloS one.

126 HEMOGLOBIN DECLINE IS ASSOCIATED WITH SVR AMONG HCV GENOTYPE 1-INFECTED PERSONS TREATED WITH PEGINTERFERON (PEG)/RIBAVIRIN (RBV): ANALYSIS FROM THE IDEAL STUDY

William M. Lee, J. Albrecht, K. Koury, 2009 .

SAT-347-MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study

R. Taub, C. Guy, M. Bashir, 2019, Journal of Hepatology.

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis

V. Wong, Z. Goodman, T. Okanoue, 2022, Gut.

Editorial: how widespread and serious is non‐alcoholic fatty liver disease in the real world? Authors' reply

Suying Li, R. Loomba, R. Wong, 2020, Alimentary Pharmacology and Therapeutics.

Hepatic mast cell concentration directly correlates to stage of fibrosis in NASH.

D. Broadwater, Katherine M. Cebe, S. Harrison, 2019, Human pathology.

SAT-302-Predicting the severity of hepatic steatosis and fibrosis by transient elastography and MRI-based techniques in adults patients with suspected NAFLD

V. Paradis, P. Bedossa, J. Aden, 2019, Journal of Hepatology.

MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study

R. Taub, J. Frias, N. Alkhouri, 2018 .

Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension.

J. Chan, P. Thuluvath, J. Bosch, 2019, Journal of hepatology.

SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis

P. Kwo, M. Hellerstein, E. Gane, 2019, Journal of Hepatology.

LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension

J. Chan, P. Thuluvath, J. Bosch, 2019, Journal of Hepatology.

PS-111-Six month interim results of MSDC-0602 K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444)

K. Cusi, A. Sanyal, H. Dittrich, 2019, Journal of Hepatology.

NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks

R. Banerjee, M. Jaros, C. Guy, 2018 .

Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study

V. Wong, F. Tacke, B. Wiens, 2016 .

Prevalence and stratification of NAFLD/NASH in a UK and US cohort using non-invasive multiparametric MRI

S. Neubauer, R. Banerjee, V. Bachtiar, 2018 .

A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension

N. Chalasani, P. Traber, Z. Goodman, 2018 .

NAFLD and NASH Biomarker Qualification in the LITMUS consortium - Lessons learned.

M. Karsdal, D. Schuppan, J. Dufour, 2022, Journal of hepatology.

R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

G. Everson, D. Nelson, M. Shiffman, 2008, Hepatology.

High relapse rate seen at week 72 for patients treated with R1626 combination therapy

G. Everson, D. Nelson, M. Shiffman, 2008, Hepatology.

993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN

G. Everson, D. Nelson, M. Shiffman, 2008 .

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension.

H. Conjeevaram, N. Chalasani, D. Rockey, 2019, Gastroenterology.

A Post-Hoc Analysis ofthe Golden505 Trial Demonstrates Histological and Cardiometabolic Efficacy of Elafibranor-120 Mg in Patients with Moderate or Severe Nash That Are Eligible for Pharmacotherapy

P. Bedossa, J. Drenth, A. Sanyal, 2016 .

Improvement in NASH histological activity highly correlates with fibrosis regression

P. Bedossa, A. Sanyal, D. Hum, 2016 .

GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial

Michael I. Miller, R. Andrade, F. Nevens, 2019, Journal of Hepatology.

Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD‐related cirrhosis

M. Noureddin, W. Ayoub, T. Todo, 2022, Hepatology.

NGM282, an engineered analogue of FGF19, significantly improves markers of bile acid synthesis, hepatic injury and fibrosis in PSC patients: Results of a phase 2, multicenter, randomized, doubleblind, placebo-controlled trial

M. Karsdal, J. Trotter, J. Drenth, 2018 .

Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis

P. Bedossa, A. Sanyal, D. Hum, 2017 .

Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH

P. Kwo, M. Hellerstein, E. Gane, 2018 .

JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study

C. Moylan, A. Diehl, M. Abdelmalek, 2018 .

938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH

J. Dufour, S. Beckebaum, J. Trotter, 2019, American Journal of Gastroenterology.

Technical success rate of MR elastography in a population without known liver disease

C. Lisanti, Ryan B. Schwope, S. Harrison, 2020, Abdominal Radiology.

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

K. Cusi, A. Feldstein, M. Goros, 2014, Journal of hepatology.

Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study

Robert L. Martin, D. Bernstein, S. Bergheanu, 2018 .

R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

G. Everson, D. Nelson, M. Shiffman, 2008, Hepatology.

Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study

P. Bossuyt, M. Allison, J. Dufour, 2023, Hepatology.